CN Patent

CN111683936B — 多取代苯环化合物、制备方法及其用途

Assigned to Suzhou Sinoway Pharmaceutical Technology Co ltd · Expires 2021-08-20 · 5y expired

What this patent protects

本发明提供了一种式(I)所示的新型EZH2抑制剂化合物以及使用该抑制剂化合物预防或治疗EZH2介导的疾病的用途。

USPTO Abstract

本发明提供了一种式(I)所示的新型EZH2抑制剂化合物以及使用该抑制剂化合物预防或治疗EZH2介导的疾病的用途。

Drugs covered by this patent

tazemetostat-hydrobromide (TAZEMETOSTAT HYDROBROMIDE)

Patent Metadata

Patent number: CN111683936B
Jurisdiction: CN
Classification: —
Expires: 2021-08-20
Drug substance claim: No
Drug product claim: No
Assignee: Suzhou Sinoway Pharmaceutical Technology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.